The synergy between alkylating agents and ERCC1–XPF inhibitors is p53 dependent
Our results confirm the mechanism of action of our ERCC1-XPF inhibitor and give important additional data on this approach to enhance the activity of already existing cancer drugs.
Authors
- Charles Dumontet (ORCID: https://orcid.org/0000-0003-1875-134X)
- Ahmed H. Elmenoufy (ORCID: https://orcid.org/0000-0002-5157-9169)
- Gloria Ciniero (ORCID: https://orcid.org/0000-0001-6258-1806)
- F. G. West (ORCID: https://orcid.org/0000-0001-7419-2314)
- Michael Weinfeld (ORCID: https://orcid.org/0000-0002-8773-1425)
- Lars Petter Jordheim (ORCID: https://orcid.org/0000-0003-3948-7090)
- Tiago Marques Pedro (ORCID: https://orcid.org/0000-0002-1767-0321)
- Francesco Gentile (ORCID: https://orcid.org/0000-0001-8299-1976)
- Emeline Cros‐Perrial
- Jack A. Tuszyński (ORCID: https://orcid.org/0000-0001-9976-0429)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- University of Ottawa (CA)
- University of Alberta (CA)
- Inserm (FR)
- Misr University for Science and Technology (EG)
- Politecnico di Torino (IT)
- Northern Alberta Institute of Technology (CA)
- Centre Léon Bérard (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Agricultural Institute of Canada (CA)
- Ottawa Institute of Systems Biology
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1111/fcp.13043
- Citations
- 4
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Olav Raagholt og Gerd Meidel Raagholts stiftelse